Professor John Atack
Prosiectau fel Prif Ymchwiliwr
- Allosteric modulators of extrasynaptic GABAA receptors for the treatment of postpartum depression (01.01.2022 - 30.06.2024)
- Allosteric modulators of spinal cord glycine receptors for the treatment of chronic pain (01.02.2023 - 31.01.2025)
- Alpha-GABAa receptor modulators for the treatment of cognitive impairment associated with Huntington's disease (01.08.2017 - 30.09.2022)
- Cardiff Translational Drug Discovery Centre (CTDDC) (01.09.2017 - 31.08.2022)
- Developing small molecules as a neurosteroid replacement strategy for treating postpartum psychosis (01.04.2021 - 31.12.2023)
Prosiectau fel Cyd-Ymchwiliwr
- Assay development and high-throughput screening for the identification of novel small molecules with a potential to reduce the NEAT1_2-mediated cytokine storm in COVID-19 (01.11.2020 - 31.03.2021)
- Developing tools to monitor expression of IncRNA NEAT1 isoforms for basic research and drug discovery (01.07.2019 - 31.10.2021)
- Identification of selective positive modulators of GlyRα3 for the treatment of neuropathic and inflammatory pain (01.06.2021 - 31.08.2021)
- Integrating genetic, clinical and phenotypic data to advance stratification, prediction and treatment in mental health (31.03.2018 - 31.03.2021)
- KAT2A/B PROTACs targeting differentiation in leukemic Stem Cells and blasts for the treatment of AML (01.01.2024 - 31.12.2025)